Randomised trial of growth hormone in short normal girls

McCaughey, Elizabeth

doi:10.1016/s0140-6736(00)80011-2

Cited by 34 publications

(68 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Inclusion criteria for participants were broadly similar, specifying short normal children less than the 3rd percentile in height, with no chronic illness or dysmorphic syndromes. Five studies 23,[38][39][40]43 included children who were prepubertal, and two studies 37,41 had pubertal children, one of which included girls only. 37 Six of the trials 23,37-41 compared GH-treated children with untreated controls, with an additional treatment group receiving luteinising hormone-releasing hormone analogue (LHRHa) to delay puberty in one trial, 41 and an additional group of patients who did not give consent to randomisation in another trial.…”

Section: Rctsmentioning

confidence: 99%

“…Five studies 23,[38][39][40]43 included children who were prepubertal, and two studies 37,41 had pubertal children, one of which included girls only. 37 Six of the trials 23,37-41 compared GH-treated children with untreated controls, with an additional treatment group receiving luteinising hormone-releasing hormone analogue (LHRHa) to delay puberty in one trial, 41 and an additional group of patients who did not give consent to randomisation in another trial. 37 Two studies 42,43 were placebo controlled, with an additional observation group in one.…”

Section: Rctsmentioning

confidence: 99%

“…37 Six of the trials 23,37-41 compared GH-treated children with untreated controls, with an additional treatment group receiving luteinising hormone-releasing hormone analogue (LHRHa) to delay puberty in one trial, 41 and an additional group of patients who did not give consent to randomisation in another trial. 37 Two studies 42,43 were placebo controlled, with an additional observation group in one. 43 Two of the three earlier trials used a dose of 0.3 mg/kg/week, 38,43 and one used either 0.2 or 0.4 mg/kg/week.…”

Section: Rctsmentioning

confidence: 99%

See 2 more Smart Citations

Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation

Bryant

Cave

Mihaylova

et al. 2002

Health Technol Assess

139

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK.We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he NHS R&D Health Technology Assessment (HTA) Programme was set up in 1993 to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS.The research reported in this monograph was commissioned by the HTA Programme on behalf of the National Institute for Clinical Excellence (NICE). Technology assessment reports are completed in a limited time to inform the appraisal and guidance development processes managed by NICE. The review brings together evidence on key aspects of the use of the technology concerned. However, appraisals and guidance produced by NICE are informed by a wide range of sources.The research reported in this monograph was funded as project number 00/21/01.The views expressed in this publication are those of the authors and not necessarily those of the HTA Programme, NICE or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for any recommendations made by the authors. Criteria for inclusion in the HTA monograph seriesRe...

show abstract

Section: Rctsmentioning

confidence: 99%

Section: Rctsmentioning

confidence: 99%

Section: Rctsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation

Bryant

Cave

Mihaylova

et al. 2002

Health Technol Assess

139

View full text Add to dashboard Cite

show abstract

“…Twenty studies related to the effect of treatment with growth hormone on the adult height of children with ISS with a total sample size of 1,517 were included in the meta-analysis ( Fig. 1 and Table 1 [10,11,[15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30][31][32] When results of studies were combined using random effects model, SMD for treatment start height was -1.64 (95% CI: -2.01 to -1.28) which is equal to 5% (their height was higher than 5% of participants) (Fig. 3).…”

Section: Resultsmentioning

confidence: 99%

The Effect of Growth Hormone Treatment on Adult Height of Children With Idiopathic Short Stature: A Systematic Review and Meta-Analyses

et al. 2017

View full text Add to dashboard Cite

Idiopathic short stature (ISS) is a kind of low height among children in which children's height is more than 2 standard deviation (SD) scores below the mean score of the height of other children with the same age and gender. It is one of the disorders that physicians use growth hormone for its treatment. Therefore, the purpose of the current study was to investigate the effect of growth hormone treatment on the adulthood height of children with ISS through meta-analysis method. In total 20 studies with a sample size of 1,517 were included in the meta-analysis through searching in external databases, including Web of science, Pubmed, Cochran, Medline, Embase, Springer, Scopus, and Science Direct using mesh keywords as growth hormone, final height, adult height, and idiopathic short stature. Mean score and SD were utilized for measuring any increase in height growth and random effect model was used for combining studies. Further, I 2 index was used for determining the heterogeneity of studies. Results indicated that before treatment, according to standard mean difference percentile of children's height was -1.64 (95% confidence interval (CI): -2.01 to -1.28) which is equal to 5%. After treatment, according to standard mean difference percentile of children's height came out to be 0.11 (95% CI: 0.07 -0.14) which is equal to 54.38%. This indicates that percentile of children's height has increased as a result of treatment with growth hormone. Through combining the results of all studies, the mean score for participants' height before treatment was 5% and after treatment it reached 54%. Therefore, obtained mean difference for adult height after treatment with growth hormone was reported to be more than 1.4 SD score (about 7.6 cm). Growth hormone can be influential in increasing the adult height of children with ISS.

show abstract

“…Thus, in the past, many children with idiopathic short stature received GH treatment despite a lack of definitive evidence for its efficacy. A meta-analysis (19), which included one small randomized trial (20) and three studies with non-randomized, untreated controls, reported a 5-6 cm difference in adult height between treatment (mean GH dose, 0.31 mg/kg per week) and control groups.…”

Section: Efficacy Of Gh Treatment In Issmentioning

confidence: 99%

Management of children with idiopathic short stature

Dunkel

2006

eur j endocrinol

View full text Add to dashboard Cite

The Food and Drug Administration (FDA) approved the use of biosynthetic GH for the treatment of children with idiopathic short stature (ISS) in the US in 2003. Primarily, the decision was based on two studies: a randomized placebo-controlled study and a dose-response study, both demonstrating an increase in adult height over the predicted height at baseline and over placebo-treated controls by an average of 4-7 cm. Despite these data and FDA approval of GH treatment for ISS, there is still a significant controversy among paediatric endocrinologists about how, and to what extent, GH should be used in this indication. GH is clearly efficacious in several growth disorders and has the potential to alleviate debilitating short stature. However, it has been questioned whether ISS should be considered a condition warranting pharmacological treatment, whether the degree of morbidity of untreated ISS is clinically significant, and whether improved psychosocial status or well-being is achieved through GH treatment and height gain. The benefits must outweigh treatment costs and risks to justify GH treatment in ISS. The safety of GH treatment in ISS has been the main subject in two recent articles from pharmaceutical companies that conducted the pioneering studies mentioned earlier. No new safety concerns were observed in the ISS populations, but there were some limitations in study designs that prevent clinicians, their patients and families from 'resting assured'. Studies addressing these controversial issues are needed before the widespread use of GH treatment in ISS is warranted. European Journal of Endocrinology 155 S35-S38

show abstract

Randomised trial of growth hormone in short normal girls

Abstract: Growth-hormone therapy effectively increased height SD score among short normal girls started on treatment in early to mid childhood, with no untoward effect on pubertal progression.

Cited by 34 publications

References 0 publications

Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation

Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation

The Effect of Growth Hormone Treatment on Adult Height of Children With Idiopathic Short Stature: A Systematic Review and Meta-Analyses

Management of children with idiopathic short stature

Contact Info

Product

Resources

About